The Company is a contract research organization (CRO) with expertise in preclinical, in vitro drug discovery research for the biotech and pharmaceutical end markets in the Northeast, United States.

Key Aspects
· The Company produced strong revenue, gross profit, and adjusted EBITDA
growth with compound annual growth rates (CAGRs) of 8.5%, 11.1%, and 16.1%,
respectively, from 2022 through the trailing twelve months (TTM) ending
June 30, 2025
· The Company generated average gross profit margin and adjusted EBITDA
margin of 43.0% and 15.5%, respectively, from 2022 through 2024
· The Company's wide array of research services has helped secure repeat
customers through service expansion
· Annual recurring revenue averaged 60.3% of total revenue from 2020 through 2023
·Financials as of 6/25
REF-BN000055974